| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
|
Arthritis Rheum
|
2010
|
18.82
|
|
2
|
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
|
Ann Rheum Dis
|
2010
|
12.12
|
|
3
|
Treating rheumatoid arthritis to target: recommendations of an international task force.
|
Ann Rheum Dis
|
2010
|
10.97
|
|
4
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
|
Ann Rheum Dis
|
2013
|
10.92
|
|
5
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
|
Ann Rheum Dis
|
2010
|
10.03
|
|
6
|
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
|
Arthritis Rheum
|
2011
|
6.28
|
|
7
|
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
|
Ann Rheum Dis
|
2011
|
4.15
|
|
8
|
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
|
Arthritis Rheum
|
2008
|
3.62
|
|
9
|
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.
|
Ann Rheum Dis
|
2010
|
2.91
|
|
10
|
Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
|
Rheumatology (Oxford)
|
2009
|
2.73
|
|
11
|
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
|
Arthritis Rheum
|
2010
|
2.68
|
|
12
|
Sustained remission with etanercept tapering in early rheumatoid arthritis.
|
N Engl J Med
|
2014
|
2.54
|
|
13
|
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
|
Arthritis Rheum
|
2004
|
2.44
|
|
14
|
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment.
|
Arthritis Rheum
|
2008
|
2.41
|
|
15
|
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.
|
Arthritis Res Ther
|
2008
|
2.15
|
|
16
|
Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort.
|
Arthritis Care Res (Hoboken)
|
2013
|
2.09
|
|
17
|
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report.
|
Arthritis Rheum
|
2010
|
1.94
|
|
18
|
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
|
Arthritis Rheum
|
2011
|
1.83
|
|
19
|
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.
|
Joint Bone Spine
|
2006
|
1.77
|
|
20
|
Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries.
|
Arthritis Rheum
|
2008
|
1.76
|
|
21
|
Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity.
|
Arthritis Rheumatol
|
2014
|
1.71
|
|
22
|
Switching between anti-TNFalpha agents: what is the evidence?
|
Joint Bone Spine
|
2004
|
1.61
|
|
23
|
Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
|
J Rheumatol
|
2011
|
1.60
|
|
24
|
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I.
|
Ann Rheum Dis
|
2010
|
1.53
|
|
25
|
Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis.
|
J Rheumatol
|
2006
|
1.53
|
|
26
|
Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.
|
J Rheumatol
|
2012
|
1.52
|
|
27
|
The TNF family member APRIL dampens collagen-induced arthritis.
|
Ann Rheum Dis
|
2012
|
1.49
|
|
28
|
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.
|
Ann Rheum Dis
|
2009
|
1.48
|
|
29
|
The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients.
|
Joint Bone Spine
|
2011
|
1.41
|
|
30
|
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
|
J Biol Chem
|
2005
|
1.41
|
|
31
|
Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
|
Ann Rheum Dis
|
2012
|
1.39
|
|
32
|
Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
|
J Rheumatol
|
2013
|
1.39
|
|
33
|
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
|
Ann Rheum Dis
|
2012
|
1.33
|
|
34
|
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis.
|
Arthritis Res Ther
|
2006
|
1.27
|
|
35
|
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.
|
J Rheumatol
|
2005
|
1.23
|
|
36
|
A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years.
|
Joint Bone Spine
|
2009
|
1.23
|
|
37
|
Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study.
|
Arthritis Res Ther
|
2008
|
1.22
|
|
38
|
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
|
Arthritis Rheum
|
2003
|
1.21
|
|
39
|
A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.
|
Ann Rheum Dis
|
2010
|
1.20
|
|
40
|
Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
|
Rheumatology (Oxford)
|
2011
|
1.20
|
|
41
|
Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis.
|
Ann Rheum Dis
|
2012
|
1.18
|
|
42
|
Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.
|
Joint Bone Spine
|
2006
|
1.16
|
|
43
|
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
|
Arthritis Res Ther
|
2009
|
1.14
|
|
44
|
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.
|
Ann Rheum Dis
|
2012
|
1.11
|
|
45
|
Understanding emerging treatment paradigms in rheumatoid arthritis.
|
Arthritis Res Ther
|
2011
|
1.10
|
|
46
|
Non-drug treatment (excluding surgery) in rheumatoid arthritis: clinical practice guidelines.
|
Joint Bone Spine
|
2009
|
1.09
|
|
47
|
Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.
|
Arthritis Res Ther
|
2009
|
1.06
|
|
48
|
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
|
Arthritis Res Ther
|
2012
|
1.05
|
|
49
|
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
|
Arthritis Rheum
|
2009
|
1.04
|
|
50
|
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2011
|
1.01
|
|
51
|
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.
|
Joint Bone Spine
|
2007
|
1.01
|
|
52
|
Treatment of chronic knee synovitis with arthroscopic synovectomy: longterm results.
|
J Rheumatol
|
2002
|
1.01
|
|
53
|
EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria.
|
Ann Rheum Dis
|
2013
|
0.97
|
|
54
|
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.
|
Joint Bone Spine
|
2007
|
0.96
|
|
55
|
Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.95
|
|
56
|
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
|
J Rheumatol
|
2011
|
0.95
|
|
57
|
Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis.
|
Clin Exp Rheumatol
|
2011
|
0.94
|
|
58
|
Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion.
|
Joint Bone Spine
|
2005
|
0.93
|
|
59
|
Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
|
Ann Rheum Dis
|
2012
|
0.93
|
|
60
|
CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2013
|
0.92
|
|
61
|
Tumor necrosis factor-alpha blockers in SAPHO syndrome.
|
J Rheumatol
|
2010
|
0.92
|
|
62
|
Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies.
|
Clin Exp Rheumatol
|
2012
|
0.92
|
|
63
|
First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.91
|
|
64
|
Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort.
|
Arthritis Res Ther
|
2012
|
0.91
|
|
65
|
Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.
|
Arthritis Rheumatol
|
2014
|
0.90
|
|
66
|
Influence of sex on disease severity in patients with rheumatoid arthritis.
|
J Rheumatol
|
2005
|
0.89
|
|
67
|
Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts.
|
Cytokine
|
2010
|
0.88
|
|
68
|
Scurvy as the presenting illness of Whipple's disease exacerbated by treatment with etanercept in a patient with ankylosing spondylitis.
|
J Rheumatol
|
2010
|
0.88
|
|
69
|
Arthritis after infection with Chikungunya virus.
|
Best Pract Res Clin Rheumatol
|
2011
|
0.88
|
|
70
|
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
|
Rheumatology (Oxford)
|
2012
|
0.87
|
|
71
|
Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase.
|
Ann Rheum Dis
|
2013
|
0.87
|
|
72
|
Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.
|
J Rheumatol
|
2006
|
0.87
|
|
73
|
Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort.
|
Rheumatology (Oxford)
|
2009
|
0.86
|
|
74
|
Ability of oblique foot radiographs to detect erosions in early arthritis: results in the ESPOIR cohort.
|
Arthritis Rheum
|
2008
|
0.85
|
|
75
|
The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis.
|
Cytokine
|
2013
|
0.85
|
|
76
|
Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion.
|
Joint Bone Spine
|
2005
|
0.84
|
|
77
|
Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort.
|
Ann Rheum Dis
|
2012
|
0.84
|
|
78
|
Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2011
|
0.84
|
|
79
|
Lymphotoxin α revisited: general features and implications in rheumatoid arthritis.
|
Arthritis Res Ther
|
2011
|
0.84
|
|
80
|
Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.
|
Joint Bone Spine
|
2006
|
0.83
|
|
81
|
Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion.
|
Joint Bone Spine
|
2009
|
0.82
|
|
82
|
Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.
|
Joint Bone Spine
|
2007
|
0.82
|
|
83
|
Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.
|
Joint Bone Spine
|
2010
|
0.82
|
|
84
|
Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.
|
Ann Rheum Dis
|
2013
|
0.82
|
|
85
|
Understanding the patient perspective - results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey.
|
Clin Exp Rheumatol
|
2013
|
0.82
|
|
86
|
Polymorphism of HLA-DMA and DMB alleles in patients with systemic lupus erythematosus.
|
J Rheumatol
|
2003
|
0.82
|
|
87
|
Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis.
|
Joint Bone Spine
|
2006
|
0.81
|
|
88
|
Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study.
|
J Rheumatol
|
2012
|
0.81
|
|
89
|
Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials.
|
J Rheumatol
|
2012
|
0.81
|
|
90
|
Mesenteric and splenic cat-scratch disease during etanercept therapy.
|
Rheumatology (Oxford)
|
2009
|
0.81
|
|
91
|
High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study.
|
Arthritis Res Ther
|
2014
|
0.80
|
|
92
|
Rheumatoid arthritis and sexuality: a patient survey in France.
|
BMC Musculoskelet Disord
|
2012
|
0.80
|
|
93
|
GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate.
|
Rheumatology (Oxford)
|
2013
|
0.80
|
|
94
|
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.80
|
|
95
|
Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.
|
Rheumatology (Oxford)
|
2012
|
0.80
|
|
96
|
Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.
|
Joint Bone Spine
|
2006
|
0.80
|
|
97
|
Rheumatoid arthritis of the hand: monitoring with a simplified MR imaging scoring method--preliminary assessment.
|
Radiology
|
2010
|
0.80
|
|
98
|
Relative clinical influence of clinical, laboratory, and radiological investigations in early arthritis on the diagnosis of rheumatoid arthritis. Data from the French Early Arthritis Cohort ESPOIR.
|
J Rheumatol
|
2010
|
0.79
|
|
99
|
TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology.
|
Joint Bone Spine
|
2006
|
0.79
|
|
100
|
Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.
|
Joint Bone Spine
|
2007
|
0.79
|
|
101
|
Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.79
|
|
102
|
Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.
|
Joint Bone Spine
|
2007
|
0.79
|
|
103
|
[Rheumatoid arthritis].
|
Rev Prat
|
2006
|
0.79
|
|
104
|
Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis.
|
Arthritis Care Res (Hoboken)
|
2012
|
0.79
|
|
105
|
The new classification criteria for rheumatoid arthritis and their impact on therapeutic decisions.
|
Joint Bone Spine
|
2011
|
0.79
|
|
106
|
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort.
|
Rheumatology (Oxford)
|
2012
|
0.78
|
|
107
|
Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis.
|
Joint Bone Spine
|
2006
|
0.78
|
|
108
|
Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion.
|
Joint Bone Spine
|
2005
|
0.78
|
|
109
|
[Prescription of NSAIDs in patients treatment with platelet inhibitors or anticoagulants].
|
Presse Med
|
2003
|
0.78
|
|
110
|
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
|
Ann Rheum Dis
|
2013
|
0.78
|
|
111
|
Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DESIR cohort.
|
Ann Rheum Dis
|
2013
|
0.78
|
|
112
|
Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort.
|
Ann Rheum Dis
|
2009
|
0.78
|
|
113
|
Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts.
|
Arthritis Res Ther
|
2007
|
0.77
|
|
114
|
Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion.
|
Joint Bone Spine
|
2009
|
0.77
|
|
115
|
The 5-yr HAQ-disability is related to the first year's changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritis.
|
Rheumatology (Oxford)
|
2003
|
0.77
|
|
116
|
Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain.
|
Joint Bone Spine
|
2003
|
0.76
|
|
117
|
Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohort.
|
J Rheumatol
|
2013
|
0.76
|
|
118
|
Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study.
|
Rheumatology (Oxford)
|
2012
|
0.76
|
|
119
|
Sarcoidosis induced by tocilizumab: a paradoxical event?
|
J Rheumatol
|
2013
|
0.76
|
|
120
|
The rheumatoid shoulder: current consensus on diagnosis and treatment.
|
Joint Bone Spine
|
2005
|
0.76
|
|
121
|
Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
|
Arthritis Res Ther
|
2014
|
0.76
|
|
122
|
Etanercept tapering in rheumatoid arthritis.
|
N Engl J Med
|
2015
|
0.75
|
|
123
|
Distinct effects of soluble and membrane-bound fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients.
|
Arthritis Rheumatol
|
2014
|
0.75
|
|
124
|
Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.
|
Arthritis Res Ther
|
2009
|
0.75
|
|
125
|
Survey of the therapeutic management of rheumatoid arthritis in France: the OPALE study.
|
Clin Exp Rheumatol
|
2010
|
0.75
|
|
126
|
On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study.
|
Joint Bone Spine
|
2011
|
0.75
|
|
127
|
Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
|
Ann Rheum Dis
|
2012
|
0.75
|
|
128
|
Potential classification criteria for rheumatoid arthritis after two years: results from a French multicenter cohort.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.75
|
|
129
|
Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: development of recommendations for clinical practice based on published evidence and expert opinion.
|
Joint Bone Spine
|
2009
|
0.75
|
|
130
|
Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients.
|
Joint Bone Spine
|
2012
|
0.75
|
|
131
|
[Postoperative discitis due to Propionibacterium acnes].
|
Presse Med
|
2010
|
0.75
|
|
132
|
Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19.
|
Rheumatology (Oxford)
|
2010
|
0.75
|